Dr. James D. Jensen, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Denver (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 599
Licensed in Colorado since 2016, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Colorado School of Medicine, Denver
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CO license 56422 (first issued 2016; transferred to compact physician)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Heart of the Rockies Regional Medical Center Salida, CO
Medical groups
- Clarity Dermatology PLLC (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 599
- Services billed
- 4,914
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 848 | 129 |
| Established patient office or other outpatient visit, 20-29 minutes | 256 | 197 |
| Destruction of precancer skin growth, 1 growth | 225 | 166 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 165 | 119 |
| Biopsy of related skin growth, first growth | 133 | 107 |
| Ultrasonic guidance for placement of radiation therapy fields | 120 | 14 |
| Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | 117 | 11 |
| Superficial and/or low voltage radiation treatment delivery | 116 | 11 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 87 | 74 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 80 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 46 payments worth $1,025 in total to this clinician.
| Janssen Biotech, Inc. | $196 |
|---|---|
| UCB, Inc. | $161 |
| Leo Pharma Inc. | $143 |
| Organogenesis Inc. | $141 |
| Novartis Pharmaceuticals Corporation | $81.23 |
| Incyte Corporation | $56.37 |
| AbbVie Inc. | $54.71 |
| Organon LLC | $52.45 |
| Food and Beverage | $925 |
|---|---|
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 5, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $51,698 in research payments for these studies, mostly to the institutions running them.
- The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Incyte Corporation - CTP010 Additional Vitiligo Study
Avita Medical Americas, LLC - A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Argenx US, Inc. - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sanofi US Services Inc. · Completed · NCT06224348
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.